AU2020371612A1 - Anti-beta-amyloid antibody for treating Alzheimer's disease - Google Patents

Anti-beta-amyloid antibody for treating Alzheimer's disease Download PDF

Info

Publication number
AU2020371612A1
AU2020371612A1 AU2020371612A AU2020371612A AU2020371612A1 AU 2020371612 A1 AU2020371612 A1 AU 2020371612A1 AU 2020371612 A AU2020371612 A AU 2020371612A AU 2020371612 A AU2020371612 A AU 2020371612A AU 2020371612 A1 AU2020371612 A1 AU 2020371612A1
Authority
AU
Australia
Prior art keywords
antibody
subject
amount
tau
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020371612A
Other languages
English (en)
Inventor
John Beaver
Samantha BUDD HAEBERLEIN
Thierry Bussiere
Gersham DENT
Laura NISENBAUM
Roger Nitsch
Edward PLOWEY
Raj RAJAGOVINDAN
Ying TIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurimmune AG
Biogen MA Inc
Original Assignee
Neurimmune AG
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune AG, Biogen MA Inc filed Critical Neurimmune AG
Publication of AU2020371612A1 publication Critical patent/AU2020371612A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2020371612A 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating Alzheimer's disease Pending AU2020371612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
US62/924,633 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2020371612A1 true AU2020371612A1 (en) 2022-05-19

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020371612A Pending AU2020371612A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating Alzheimer's disease

Country Status (13)

Country Link
US (1) US20220372123A1 (https=)
EP (1) EP4048695A1 (https=)
JP (2) JP2022553329A (https=)
KR (1) KR20220084095A (https=)
CN (1) CN114599393A (https=)
AU (1) AU2020371612A1 (https=)
BR (1) BR112022007595A2 (https=)
CA (1) CA3158513A1 (https=)
CO (1) CO2022004902A2 (https=)
IL (1) IL292363A (https=)
JO (1) JOP20220092A1 (https=)
MX (1) MX2022004678A (https=)
WO (1) WO2021081101A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2019152706A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a6a antibodies and methods of use thereof
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023081194A2 (en) * 2021-11-03 2023-05-11 Biogen Ma Inc. Methods for treating alzheimer's disease
AU2022439338A1 (en) * 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
US20240207362A1 (en) * 2022-10-25 2024-06-27 Institute For Basic Science (Ibs) Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
WO2008141321A1 (en) * 2007-05-14 2008-11-20 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2598882B1 (en) * 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
US20150315267A1 (en) * 2012-12-07 2015-11-05 Thierry Bussiere A method of reducing brain amyloid plaques using anti-ab antibodies
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN114796481A (zh) * 2016-06-07 2022-07-29 生物基因国际神经科学有限责任公司 治疗阿尔茨海默病的方法

Also Published As

Publication number Publication date
WO2021081101A1 (en) 2021-04-29
IL292363A (en) 2022-06-01
CA3158513A1 (en) 2021-04-29
JP2026012271A (ja) 2026-01-23
CO2022004902A2 (es) 2022-07-08
BR112022007595A2 (pt) 2022-08-23
KR20220084095A (ko) 2022-06-21
JOP20220092A1 (ar) 2023-01-30
CN114599393A (zh) 2022-06-07
EP4048695A1 (en) 2022-08-31
US20220372123A1 (en) 2022-11-24
MX2022004678A (es) 2022-08-15
JP2022553329A (ja) 2022-12-22

Similar Documents

Publication Publication Date Title
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
US20260091109A1 (en) Method for Treating Alzheimer's Disease
US20220281963A1 (en) Methods for treating alzheimer's disease
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
TW202313111A (zh) 治療阿茲海默症之方法
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
CN121335711A (zh) 使用抗Aβ初原纤维抗体的治疗方法
NZ788486A (en) Methods for treating Alzheimer's disease